Move to topTop
June 07, 2021

LEUVEN, BELGIUM - June 7, 2021 - Terumo Pharmaceutical Solutions, a division of Terumo Corporation (TSE: 4543) announced today that pharma's leading drug developers continue to combine the company's injection technologies with advanced parenteral therapeutics to support accurate simplified administration and prevent needlestick injury.

For example, a Terumo Pharmaceutical Solutions client, ViiV Healthcare, a global specialist HIV company recently announced the FDA approval of Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is delivered through two injectable medicines -- ViiV Healthcare's Cabotegravir and Janssen's Rilpivirine. For injections in the clinical setting, Cabenuva is combined in a kit with Terumo's SurGuard®3 safety hypodermic needles and 5ml LL disposable syringes for convenience, reduced cross contamination and the aim to reduce the probability for needlesticks.

Cabenuva is a recent evidence of the continued success Terumo Pharmaceutical Solutions injection technologies have, winning a place in the therapeutic value chain of products from today's top drug developers.

We work with the world's most prominent vaccine producers and advanced drug innovators to support effective delivery of their parenteral products," commented Tetsuya Kumei, Division President of the Alliance Division, Terumo Corporation. "Successful drug development is extremely challenging and parenteral administration only adds to the barriers that prevent program success. Over the years, we've supported our clients to overcome their toughest drug delivery and product packaging challenges. We are incredibly proud to be supporting innovation in the pharma industry and to be playing a role in the delivery of Cabenuva."

Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety. Globally trusted for quality and precision, Terumo offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services as well as a portfolio of injection, infusion, and primary packaging solutions. Terumo Pharmaceutical Solutions has decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to the latest stages of product commercialization to optimize critical aspects of parenteral drug delivery. Our comprehensive parenteral delivery product portfolio of injection, infusion, and primary packaging solutions offers innovative drug delivery technologies ready for today's most demanding applications.

  • 20210607.png

    *Please refer to the IFU provided with the treatment kit

    About Terumo

    Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

    Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


    Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.